<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-296 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-296</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-296</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-48359834</p>
                <p><strong>Paper Title:</strong> Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?</p>
                <p><strong>Paper Abstract:</strong> Recent changes in lung cancer care, including new approvals in first line and the introduction of high-throughput molecular technologies in routine testing led us to question ourselves on how deeper molecular testing may be helpful for the optimal use of targeted drugs. In this article, we review recent results in the scope of personalized medicine in lung cancer. We discuss biomarkers that have a therapeutic predictive value in lung cancer with a focus on recent changes and on the clinical value of large scale sequencing strategies. We review the use of second- and third-generation EGFR and ALK inhibitors with a focus on secondary resistance alterations. We discuss anti-BRAF and anti-MEK combo, emerging biomarkers as NRG1 and NTRKs fusions and immunotherapy. Finally, we discuss the different technical issues of comprehensive molecular profiling and show how large screenings might refine the prediction value of individual markers. Based on a review of recent publications (2012â€“2018), we address promising approaches for the treatment of patients with lung cancers and the technical challenges associated with the identification of new predictive markers.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e296.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e296.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_prevalence_ethnic</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor (EGFR) mutation prevalence across ethnic populations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Review-reported prevalence and characteristics of somatic EGFR mutations in NSCLC with explicit comparisons between Asian and Caucasian (non-Asian) populations, and discussion of proposed explanations for ethnic differences (smoking patterns, environmental hypotheses, and molecular-signature analyses).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Clinical Medicine Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asian and Caucasian (non-Asian) populations reported as comparison groups</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Asia for Asian data; Western/Caucasian populations for Caucasian data (not tied to a single country in this review)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported ranges in the review: ~40% in Asiatic patients versus ~11-17% in Caucasian patients</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Almost all EGFR mutations in exons 18-21: exon 19 in-frame deletions (del19) ~40-50% of EGFR mutations; exon 21 L858R substitution ~30-40%; uncommon mutations (10-18%) include exon 20 insertions and some exon 18 variants; resistance-associated exon 20 T790M and tertiary C797S also discussed.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>Asian: ~40% EGFR-mutated NSCLC; Caucasian: ~11-17% EGFR-mutated NSCLC (as stated in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>EGFR mutations are more common in never-smokers; smokers or former smokers are associated with a lower incidence of EGFR mutation. The review also notes a higher proportion of never-smokers among Asian patients (up to ~40% never-smokers in Asians vs 10-15% in Caucasians).</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>EGFR mutations are mainly associated with female gender.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td>The review lists hypotheses for higher NSCLC/EGFR rates in Asian never-smokers including second-hand smoke, cooking fumes, and other specific environmental factors; however it cites whole-genome sequencing work concluding the elevated rate of NSCLC in Asian never-smokers was unlikely to be due to second-hand smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Differences in smoking patterns (higher proportion of never-smokers among Asians) are presented as a likely contributing factor to higher EGFR mutation prevalence because targetable oncogenic drivers are more common in never-smokers; cooking practices (as a lifestyle/environmental exposure) are mentioned as a hypothesized factor.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Molecular-signature analyses (whole-genome sequencing) are cited as evidence refuting second-hand smoke as the driver of the higher rate in Asian never-smokers; the review implies that population composition (higher never-smoker fraction) and tumor molecular subtypes contribute to observed ethnic differences. The paper does not propose specific hereditary/genetic germline mechanisms or detection-bias explanations.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Non-small cell lung cancer (NSCLC), predominantly adenocarcinoma for EGFR-mutated cases.</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>General statement: EGFR-mutated advanced NSCLC patients derive clear benefit from EGFR-TKIs (first-, second-, and third-generation agents discussed); EGFR-TKIs are the preferred first-line therapy in EGFR-mutated advanced NSCLC. No ethnicity-specific response rates are provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?', 'publication_date_yy_mm': '2018-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Whole-genome sequencing of Asian lung cancers: Second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers <em>(Rating: 2)</em></li>
                <li>EGFR mutation testing practices within the Asia Pacific region: Results of a multicenter diagnostic survey <em>(Rating: 2)</em></li>
                <li>EGFR mutation, smoking, and gender in advanced lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>